Researchers Use ScreenCell® To Enrich Breast Cancer CTC Biomarkers
PARIS–(BUSINESS WIRE)–ScreenCell has entered into a collaborative study with the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center of Thomas Jefferson University in Philadelphia, to evaluate the effectiveness of ScreenCell’s proprietary devices and protocols for enrichment of Circulating Tumor Cells (CTCs) from peripheral blood. ScreenCell technology separates CTCs from blood components by differential size.
“We are delighted to be working with the research team at Jefferson to help accelerate the characterization of circulating tumor cells from breast cancer patients. We are committed to help cancer researchers address these challenges.”
“Although we have utilized CTC enumeration techniques for blood samples from patients based on whether the cell is producing the EpCam marker (Epithelial Cell Adhesion Molecule) on the surface of the cell, we have shown that in 30-40% of metastatic breast cancer cases, such tests could be negative,” said Massimo Cristofanilli MD, Director of the Jefferson Breast Care Center. “These cases are especially important for us to understand due to the high mutation rate. The molecular characterization of these EpCam negative cells assessing individual gene sequence and protein expression is an important step to improve our efforts in advancing precision medicine. We are hopeful that the ScreenCell technology and enrichment protocols will enable us to achieve these research objectives.”
“Our scientists at ScreenCell Laboratories work closely with clinical research sites in order to provide the most effective customized protocols, and we have hosted Dr. Zhaomei Mu from Dr. Cristofanilli’s lab at our laboratory in Paris. We look forward to working with Dr. Cristofanilli’s entire research team,” said Georges Uzan PhD, Chief Scientific Officer at ScreenCell.
David Znaty, ScreenCell’s CEO, stated, “We are delighted to be working with the research team at Jefferson to help accelerate the characterization of circulating tumor cells from breast cancer patients. We are committed to help cancer researchers address these challenges.”
ScreenCell, headquartered in Paris, France is a privately held company dedicated to provide products, protocols and training support for cancer research facilities to characterize Circulating Tumor Cells and other rare cells in biological specimens. For more information please visit www.screencell.com